Chronic Kidney Disease Guidelines

Prevention of Progression of Kidney Disease

Contact Guideline Convenor: If you wish to contact the Convenor for these guidelines , they can be contacted via Denise Campbell, Senior Project Officer, CARI Guidelines Office: DeniseC2@chw.edu.au

All guidelines are in .PDF format and require Adobe Acrobat for viewing and printing

PLEASE NOTE: A new Guideline on the diagnosis, prevention & management of chronic kidney disease in type 2 diabetes, has recently been published [June 2009].The information in this guideline supercedes the CARI Guideline subtopics on diabetic nephropathy that are marked with an asterisk [*] in the list below.

Please refer to this new guideline:
National Evidence Based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes

NHMRC Guideline Summary: Prevention and management of CKD in people with type 2 diabetes

new A shortened version of this guideline has now been published by CARI and is now found under the heading Type 2 Diabetes: Kidney Disease under the Chronic Kidney Disease section of these Guidelines.

Prevention of Progression of Kidney Disease Status
*ACE inhibitor treatment in diabetic nephropathy Published April 2006
*ACE inhibitor and angiotensin II antagonist combination treatment Published April 2006
Acidosis Published April 2006
Analgesic-associated kidney disease Published April 2006
*Angiotensin II antagonists Published April 2006
*Antihypertensive therapy in diabetic nephropathy Published April 2006
Autosomal-dominant polycystic kidney disease Published Feb 2007
Blood pressure control: targets Published April 2006
Blood pressure control: role of specific anti-hypertensives Published April 2006
*Control of hypercholesterolaemia and progression of diabetic nephropathy Published April 2006
Dietary protein restriction Published April 2006
Early detection of patients with kidney disease Published Feb 2007
Early referral of patients with pre-end-stage kidney disease Published Feb 2007
Erythropoietin Published April 2006
Exercise Published April 2006
Focal segmental glomerulosclerosis (FSGS): treatment with steroids Published April 2006
Focal segmental glomerulosclerosis (FSGS): use of cyclosporin A Published April 2006
Focal segmental glomerulosclerosis (FSGS): cytotoxic therapy Published April 2006
Focal segmental glomerulosclerosis (FSGS): correction of secondary causes Published April 2006
Focal segmental glomerulosclerosis (FSGS): use of other therapies Published April 2006
*Glucose control and progression of diabetic nephropathy Published April 2006
Lipids Published April 2006
Membranous nephropathy: role of alkylating agents Published April 2006
Membranous nephropathy: role of steroids Published April 2006
Membranous nephropathy: role of cyclosporin therapy Published April 2006
Membranous nephropathy: use of other therapies Published April 2006
*Multifactorial therapy and the progression of diabetic nephropathy Published April 2006
Other agents Published April 2006
Other forms of dietary interventions Published April 2006
Phosphate Published April 2006
Pre-dialysis education for patients with chronic kidney disease Published Feb 2007
Pregnancy Published April 2006
*Protein restriction to prevent the progression of diabetic nephropathy Published April 2006
Reducing proteinuria Published April 2006
Reflux nephropathy Published April 2006
Regular and frequent follow-up of patients with pre-end-stage kidney disease Published Feb 2007
Renal artery stenosis Published April 2006
Smoking Published April 2006
*Smoking and the progression of diabetic nephropathy Published April 2006
*Specific effects of calcium channel blockers in diabetic nephropathy Published April 2006
Specific management of IgA nephropathy: role of steriod therapy Published April 2006
Specific management of IgA nephropathy: role of fish oil Published April 2006
Specific management of IgA nephropathy: role of triple therapy and cytotoxictherapy Published April 2006
Specific management of IgA nephropathy: role of tonsillectomy Published April 2006
Specific management of IgA nephropathy: role of cyclosporin and other therapies Published April 2006
Treatment of secondary membranous nephropathy Published April 2006
Uric acid Published April 2006
Weight reduction in obese patients with chronic kidney disease Published Feb 2007

 

Home | About CARI | Contact Us | Guidelines | For Guideline Writers
For Peer Reviewers | For Consumers | Implementation |
Annual Reports | Newsletters | Useful Links | What's New?
SEARCH the CARI website

About the CARI logo

Updated: July 25, 2010
Copyright © 2004 CARI. All Rights Reserved